J Sachau1, S-C Fabig1, S Rehm1, R Baron2. 1. Sektion Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland. 2. Sektion Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland. r.baron@neurologie.uni-kiel.de.
Abstract
BACKGROUND: The treatment of polyneuropathy includes symptomatic therapy of sensory, motor and autonomic dysfunctions. AIM: This article provides an overview of the current treatment recommendations for polyneuropathy, focusing on pain. METHODS: Current treatment guidelines will be discussed based on a literature research. RESULTS: Calcium-channel anticonvulsants gabapentin/pregabalin as well as antidepressants duloxetine and amitriptyline are recommended as first line therapeutics. Alternatively, topical therapeutics can be used in the case of localized disorders. In individual cases, opioids or other antidepressants/anticonvulsants may be effective. Pharmacological treatment is often limited due to adverse events, which affect the central nervous system in particular. DISCUSSION: In general, treatment for polyneuropathy should follow a multimodal concept and include the treatment of other symptoms. When choosing pain medication, comorbidities, patient's age and adverse events need to be taken into consideration. Phenotype-based stratification may support specialized pain therapy and achieve the best medical treatment.
BACKGROUND: The treatment of polyneuropathy includes symptomatic therapy of sensory, motor and autonomic dysfunctions. AIM: This article provides an overview of the current treatment recommendations for polyneuropathy, focusing on pain. METHODS: Current treatment guidelines will be discussed based on a literature research. RESULTS: Calcium-channel anticonvulsants gabapentin/pregabalin as well as antidepressants duloxetine and amitriptyline are recommended as first line therapeutics. Alternatively, topical therapeutics can be used in the case of localized disorders. In individual cases, opioids or other antidepressants/anticonvulsants may be effective. Pharmacological treatment is often limited due to adverse events, which affect the central nervous system in particular. DISCUSSION: In general, treatment for polyneuropathy should follow a multimodal concept and include the treatment of other symptoms. When choosing pain medication, comorbidities, patient's age and adverse events need to be taken into consideration. Phenotype-based stratification may support specialized pain therapy and achieve the best medical treatment.
Entities:
Keywords:
Adverse drug reactions; Analgesics; Anticonvulsants; Antidepressive agents; Pain management
Authors: Dyveke T Demant; Karen Lund; Jan Vollert; Christoph Maier; Märtha Segerdahl; Nanna B Finnerup; Troels S Jensen; Søren H Sindrup Journal: Pain Date: 2014-08-17 Impact factor: 6.961
Authors: David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr Journal: N Engl J Med Date: 2018-07-05 Impact factor: 91.245
Authors: Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho Journal: N Engl J Med Date: 2018-07-05 Impact factor: 91.245
Authors: William R Kennedy; Geertrui F Vanhove; Shiao-Ping Lu; Jeffrey Tobias; Keith R Bley; David Walk; Gwen Wendelschafer-Crabb; Donald A Simone; Mona M Selim Journal: J Pain Date: 2010-04-18 Impact factor: 5.820
Authors: Bianca T A de Greef; Janneke G J Hoeijmakers; Margot Geerts; Mike Oakes; Tim J E Church; Stephen G Waxman; Sulayman D Dib-Hajj; Catharina G Faber; Ingemar S J Merkies Journal: Brain Date: 2019-02-01 Impact factor: 13.501
Authors: Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace Journal: Lancet Neurol Date: 2015-01-07 Impact factor: 44.182
Authors: Ralf Baron; Christoph Maier; Nadine Attal; Andreas Binder; Didier Bouhassira; Giorgio Cruccu; Nanna B Finnerup; Maija Haanpää; Per Hansson; Philipp Hüllemann; Troels S Jensen; Rainer Freynhagen; Jeffrey D Kennedy; Walter Magerl; Tina Mainka; Maren Reimer; Andrew S C Rice; Märta Segerdahl; Jordi Serra; Sören Sindrup; Claudia Sommer; Thomas Tölle; Jan Vollert; Rolf-Detlef Treede Journal: Pain Date: 2017-02 Impact factor: 7.926